Related Experiment Video
Updated: Jan 15, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Impact of Allostatic Load on Chronic Hepatitis B and C: A Narrative Review
Chukwuemeka E Ogbu1, John N Kalu1, Maureen Ezechukwu1
1Internal Medicine, Cape Fear Valley Health, Fayetteville, USA.
Insights
Allostatic load, the body's response to chronic stress, contributes to varied hepatitis B (HBV) and C (HCV) progression by affecting immune function and inflammation. Addressing stress and social factors is key for better patient outcomes.
Area of Science:
- Immunology
- Hepatology
- Psychoneuroimmunology
Background:
- Clinical progression of chronic hepatitis B (HBV) and C (HCV) shows variability not solely explained by viral factors.
- Allostatic load, the cumulative physiological burden of chronic stress, is explored as a contributing host factor.
Purpose of the Study:
- To review the role of allostatic load in the heterogeneity of HBV and HCV clinical progression.
- To explore how allostatic load influences immune dysregulation, hepatic inflammation, and clinical outcomes in viral hepatitis.
Main Methods:
- Narrative synthesis of English-language studies from major databases and gray literature.
- Inclusion of diverse study designs (cross-sectional, cohort, clinical trials) and preclinical studies on biological mechanisms.
- Thematic summarization of findings due to significant heterogeneity.
Main Results:
- Chronic stress disrupts hepatic immune homeostasis via neuroendocrine pathways (HPA axis, sympathetic nervous system), increasing inflammation and impairing antiviral immunity.
- Psychosocial stress and depression are linked to reduced antiviral therapy adherence (especially HCV) and may worsen disease flares and fibrosis.
- Social determinants of health (poverty, trauma, incarceration) increase allostatic load, create care barriers, and exacerbate health disparities.
Conclusions:
- Allostatic load provides a biopsychosocial framework for understanding HBV/HCV heterogeneity, with a more established link in HCV.
- Clinical evidence for allostatic load's impact is limited and heterogeneous, necessitating further research.
- Future research should focus on prospective studies with standardized stress biomarkers and integrated care models addressing mental health and structural barriers.
Abstract:
The clinical progression of chronic hepatitis B (HBV) and C (HCV) is highly variable and not fully explained by virological factors alone. This narrative review explores the role of allostatic load, defined as the cumulative physiological burden of chronic stress, as a host factor that may contribute to this heterogeneity by influencing immune dysregulation, hepatic inflammation, and clinical outcomes. We conducted a narrative synthesis of English-language studies identified through PubMed, Web of Science, Scopus, PsycINFO, and gray literature. We included studies (cross-sectional, case-control, cohort studies, clinical trials, implementation studies, and policy documents) that employed any measure of psychosocial stress (validated psychometric scales/biomarkers/clinical diagnoses) and hepatitis-related clinical or virologic outcomes. Preclinical studies that described biological mechanisms were also included. Given significant heterogeneity, findings were summarized thematically. Chronic stress disrupts hepatic immune homeostasis through neuroendocrine pathways, including the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system activation, leading to Kupffer cell activation, pro-inflammatory cytokine release, and impaired antiviral immunity. Psychosocial stress and depression are associated with reduced adherence to antiviral therapy, particularly in HCV, and may influence disease flares and fibrosis progression. Structural and social determinants of health, such as poverty, trauma, adverse childhood experiences, and incarceration, impact allostatic load and create barriers to care, exacerbating health disparities in vulnerable populations. Allostatic load offers a biopsychosocial framework for HBV/HCV, but clinical evidence remains limited and heterogeneous, with a more established link in HCV. Future research should prioritize prospective studies using standardized stress biomarkers and evaluate integrated care models that address mental health and structural barriers to improve outcomes and achieve health equity.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

